Sudha Seshadri on CMS Plans to Limit Aduhelm Coverage to Clinical Trials
COMMENT I think CMS made the right call here. We need to devote the money and effort required to ensure adequate recruitment of the minoritized. It must be done, and I believe since there are now—for the first time in clinical trials of AD—real consequences for n